Bispecific checkpoint inhibitor antibodies

US10787518B2 · kind B2 · utility

Assignee

• Xencor, Inc. · US

Inventors

• Matthew Bernett · Monrovia, US
• Gregory Moore · Monrovia, US
• John Desjarlais · Pasadena, US
• Michael Hedvat · Sylvia Park, US
• Christine Bonzon · Los Angeles, US
• Alex Nisthal · Monrovia, US

Key dates

• Filing date: Jun 14, 2017
• Grant date: Sep 29, 2020
• Expiry date: Jun 14, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/94
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention is directed to compositions that include programmed cell death 1 (PD-1) binding domains and antibodies that include such PD-1 binding domains. Also provided are nucleic acid compositions that encode the binding domains and antibodies, expression vector compositions that include the nucleic acids, and host cells that include the expression vector compositions.